NCT05495867

Brief Summary

In this case-control study a bioactive implant surface was compared with traditional surfaced implants. Primary objectives: Test the implant stability in post-extractive sites, comparing traditional surfaced implants (MultiNeO CS, control group) to bioactive surfaced implants (NINA- MultiNeO NH, treatment group). Primary outcome endpoints were Implant stability, assessed through Implant stability quotient (ISQ) values and Marginal bone loss (MBL)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 9, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 10, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2023

Completed
Last Updated

September 4, 2024

Status Verified

September 1, 2024

Enrollment Period

1.4 years

First QC Date

August 9, 2022

Last Update Submit

September 1, 2024

Conditions

Keywords

dental implantbioactivationimplant surface

Outcome Measures

Primary Outcomes (5)

  • Marginal bone loss

    Radiographic evaluation of the marignal bone level around the implant using a periapical x ray. marginal bone loss is in millimeters and indicates how many millimeters of bone has been lost

    6 months after implant placement

  • Marginal bone loss

    Radiographic evaluation of the marignal bone level around the implant using a periapical x ray. marginal bone loss is in millimeters and indicates how many millimeters of bone has been lost

    12 months after implant placement

  • Implant stability

    check implant stability using resonant frequency analysis (RFA)

    immediately after implant placement

  • Implant stability

    check implant stability using resonant frequency analysis (RFA)

    30 days after implant placement

  • Implant stability

    check implant stability using resonant frequency analysis (RFA)

    45 days after implant placement

Secondary Outcomes (1)

  • insertion torque curve

    During implant placement (T0 baseline)

Study Arms (2)

NINA- MultiNeO NH

EXPERIMENTAL

implant with bioactive surface

Procedure: implant placement

MultiNeO CS

ACTIVE COMPARATOR

implant with traditional surface

Procedure: implant placement

Interventions

implant placement in edentulous area

MultiNeO CSNINA- MultiNeO NH

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with type 1-2 post extraction sites
  • Subject is 30-80 years old
  • Patient ASA 1 or 2
  • Patients with healthy periodontal conditions (Treated periodontitis, PI\<25%, BoP\<25%)
  • Patients that are willing to sign an informed consent and participate in a clinical study

You may not qualify if:

  • Absence Type 1-2 post extraction sites
  • Patient ASA 3 or 4
  • Untreated Periodontitis
  • Any sites where an implant already failed sites
  • Allergy declared to one or more medicaments to be used during treatment
  • Pregnancy (confirmed by verbal inquiry)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Studio Odont.Associato Dr.P.Cicchese E L.Canullo

Rome, Italy/Rome, 00198, Italy

Location

Related Publications (3)

  • Wennerberg A, Albrektsson T. Effects of titanium surface topography on bone integration: a systematic review. Clin Oral Implants Res. 2009 Sep;20 Suppl 4:172-84. doi: 10.1111/j.1600-0501.2009.01775.x.

    PMID: 19663964BACKGROUND
  • Han J, Lulic M, Lang NP. Factors influencing resonance frequency analysis assessed by Osstell mentor during implant tissue integration: II. Implant surface modifications and implant diameter. Clin Oral Implants Res. 2010 Jun;21(6):605-11. doi: 10.1111/j.1600-0501.2009.01909.x.

    PMID: 20666787BACKGROUND
  • Gianfreda F, Antonacci D, Raffone C, Muzzi M, Pistilli V, Bollero P. Microscopic Characterization of Bioactivate Implant Surfaces: Increasing Wettability Using Salts and Dry Technology. Materials (Basel). 2021 May 17;14(10):2608. doi: 10.3390/ma14102608.

    PMID: 34067747BACKGROUND

MeSH Terms

Conditions

AnodontiaJaw, EdentulousMouth, Edentulous

Condition Hierarchy (Ancestors)

Tooth AbnormalitiesStomatognathic System AbnormalitiesStomatognathic DiseasesTooth DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesJaw DiseasesMusculoskeletal DiseasesMouth Diseases

Study Officials

  • Luigi Canullo, DDS PhD

    Studio odontoiatrico associato Cicchese Canullo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 9, 2022

First Posted

August 10, 2022

Study Start

April 22, 2022

Primary Completion

September 15, 2023

Study Completion

September 15, 2023

Last Updated

September 4, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will share

Clinical data will be first recorded in EDC (electronic data capture). Then data will be entered into one-central computerized database. Patient adverse events will be reported, including during implant placement and throughout follow-up period. Implant details parameters and data will be recorded into EDC. The data then will be entered into one central computerized database and analyzed statistically for evaluation of the results. The study database will be designed and maintained using Microsoft Excel. an identification code will be assigned to each patient

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
the data will be available for the duration of the study
Access Criteria
the data will be available for the duration of the study

Locations